Trius expects topline data from their PhaseIII trial of Tedizolid, a next generation of the already approved Pfizer drug, linezolid by the end of the first Q. The drug appears to be more potent with less drug associated toxicity when compared to the MRSA SOC. Pfizer's linezolid brings in roughly 1.2 billion dollars a year with estimates to rise. Pfizer will be forced to buy Trius outright by the end of 2013. With 45-50 million shares outstanding you do the math.